ACCME/Disclosures. Diagnosing Mesothelioma in Limited Tissue Samples. Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016

Similar documents
Mesothelioma: diagnostic challenges from a pathological perspective. Naseema Vorajee August 2016

Mesothelioma Pathobasic. Lukas Bubendorf Pathology

ACCME/Disclosures. Case 4 USCAP Pulmonary Panel Case 4 History

Biopsy Interpretation of Spindle cell proliferations of the Serosa

Follow up of the Guidelines for Cytopathologic Diagnosis of Malignant Mesothelioma

Update: Morphologic Considerations in Mesothelioma within the Pleural and Peritoneal Cavities. Douglas J. Hartman, MD June 7, 2018

The pathologic diagnosis of malignant mesothelioma

Notice of Faculty Disclosure

How to Recognize Gynecologic Cancer Cells from Pelvic Washing and Ascetic Specimens

As part of the International Mesothelioma Interest Group

EARLY ONLINE RELEASE

ACCURACY OF IMMUNOHISTOCHEMISTRY IN EVALUATION

Presentation material is for education purposes only. All rights reserved URMC Radiology Page 1 of 98

Applications of IHC. Determination of the primary site in metastatic tumors of unknown origin

Well-differentiated Papillary Mesothelioma of the Pleura Diagnosed by Video-Assisted Thoracic Surgical Pleural Biopsy : A Case Report

Lung Tumor Cases: Common Problems and Helpful Hints

Effusion Cytology: Diagnostic Challenges

Disclosure. Relevant Financial Relationship(s) None. Off Label Usage None MFMER slide-1

Serous effusion Objectives. Cytology of Serous Effusions From basics to challenges

Guidelines for Pathologic Diagnosis of Malignant Mesothelioma. A Consensus Statement from the International Mesothelioma Interest Group

Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry

During recent decades, many studies have investigated

SELECTED DILEMMAS IN RESPIRATORY CYTOPATHOLOGY (2 CASES)

Immunohistochemistry on Fluid Specimens: Technical Considerations

The role of immunohistochemistry in surgical pathology of the uterine corpus and cervix

ACCME/Disclosures. Cribriform Lesions of the Prostate. Case

04/09/2018. Salivary Gland Pathology in the Molecular Era Old Friends, Old Foes, & New Acquaintances

Case 4 Diagnosis 2/21/2011 TGB

Case year old female presented with asymmetric enlargement of the left lobe of the thyroid

Value of antimesothelioma HBME 1 in the diagnosis of inflammatory and malignant pleural effusions

Problem 1: Differential of Neuroendocrine Carcinoma 3/23/2017. Disclosure of Relevant Financial Relationships

Update on 2015 WHO Classification of Lung Adenocarcinoma 1/3/ Mayo Foundation for Medical Education and Research. All rights reserved.

3/24/2017. Disclosure of Relevant Financial Relationships. Mixed Epithelial Endometrial Carcinoma. ISGyP Endometrial Cancer Project

Ascitic Fluid and Use of Immunocytochemistry. Mercè Jordà, University of Miami

DIAGNOSTIC SLIDE SEMINAR: PART 1 RENAL TUMOUR BIOPSY CASES

Evening Specialty Conference: Cytopathology

Original Article Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry

Unknown Slides Conference

Expression of Cytokeratin 5/6 in Epithelial Neoplasms: An Immunohistochemical Study of 509 Cases

Non Small Cell Lung Cancer Histopathology ד"ר יהודית זנדבנק

Papillary Lesions of the Breast A Practical Approach to Diagnosis. (Arch Pathol Lab Med. 2016;140: ; doi: /arpa.

3/27/2017. Disclosure of Relevant Financial Relationships. Papilloma???

Immunohistochemistry in Bone and Soft Tissue Tumors. Sahar Rassi Zankoul, MD

Differential diagnosis of HCC

Immunohistochemical profile of normal mesothelium and histiocytic/methothelial hyperplasia: a case report

Salivary Gland FNA ATYPICAL : Criteria and Controversies

ACCME/Disclosures. Case History 4/13/2016. USCAP GU Specialty Conference Case 3. Ann Arbor, MI

Mody. AIS vs. Invasive Adenocarcinoma of the Cervix

Lung Neoplasia II Resection specimens Pathobasic. Lukas Bubendorf Pathology

Post-irradiation pericardial malignant mesothelioma with deletion of p16: a case report

Cytological Sub-classification of Lung Cancer: Morphologic and Molecular Characteristics. Mercè Jordà, University of Miami

Intrahepatic cholangiocarcinoma Histologic spectrum, novel markers and molecular assays

POORLY DIFFERENTIATED, HIGH GRADE AND ANAPLASTIC CARCINOMAS: WHAT IS EVERYONE TALKING ABOUT?

GUT-C 11/30/2017. Debasmita Das, M.D. PGY-1 Danbury Hospital

Papillary Lesions of the Breast: WHO Update

Outline. Hepatocellular Carcinoma Histologic variants. HCC: Histologic variants

05/07/2018. Types of challenges. Challenging cases in uterine pathology. Case 1 ` 65 year old female Post menopausal bleeding Uterine Polyp

The Panel Approach to Diagnostics. Lauren Hopson International Product Specialist Cell Marque Corporation

NEW IHC A n t i b o d i e s

Urinary Bladder: WHO Classification and AJCC Staging Update 2017

Applications of Flow Cytometry in Diagnostic Cytology of Body Cavity Fluids

Call For A Slide Seminar Of African Cases

Papillary Lesions of the Breast

Respiratory Cytology and Ancillary diagnostic techniques. Dr Alex Rice Royal Brompton Hospital

A 53 year-old woman with a lung mass, right hilar mass and mediastinal adenopathy.

Cutaneous metastases. Thaddeus Mully. University of California, San Francisco Professor, Departments of Pathology and Dermatology

HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY

Synonyms. Nephrogenic metaplasia Mesonephric adenoma

Update on Thyroid FNA The Bethesda System. Shikha Bose M.D. Associate Professor Cedars Sinai Medical Center

Malignant pleural mesothelioma (MPM) is a rare tumor

A 60-year old Man with Left Jaw Mass. Simon Chiosea, MD University of Pittsburgh medical Center 3/15/2016

Neuroendocrine Lung Tumors Myers

INTRODUCTION TO PATHOLOGICAL TECHNIQUES. 1. Types of routine biopsy procedures 2. Special exams (IHC, FISH)

A Useful Antibody Panel for Differential Diagnosis Between Peritoneal Mesothelioma and Ovarian Serous Carcinoma in Japanese Cases

LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia

The clinically challenging entity of liver metastasis from tumors of unknown primary

Papillary adenocarcinoma of the rete testis with adjacent hyperplasia: a case report

Histopathological diagnosis of CUP

5/1/2009. Squamous Dysplasia/CIS AAH DIPNECH. Adenocarcinoma

Enterprise Interest None

5/21/2018. Prostate Adenocarcinoma vs. Urothelial Carcinoma. Common Differential Diagnoses in Urological Pathology. Jonathan I.

CASE year old male with a PET avid nodule in the left adrenal gland

BSD 2015 Case 19. Female 21. Nodule on forehead. The best diagnosis is:

Neuroendocrine neoplasms of the lung

Case 26 Male 37. Right jawline 5mm nodule?keloid. The best diagnosis is:

Clinicopathological Study on Malignant Pleural Mesotheliomas

Renal tumours: use of immunohistochemistry & molecular pathology. Dr Lisa Browning John Radcliffe Hospital Oxford

New Developments in Immunohistochemistry for Gynecologic Pathology

Atypical Hyperplasia/EIN

The 2015 World Health Organization Classification for Lung Adenocarcinomas: A Practical Approach

What s (new) and Important in Reporting of Uterine Cancers Katherine Vroobel The Royal Marsden

Immunohistochemistry in Peritoneal Mesothelioma. A Single-Center Experience of 244 Cases

Disclosures. Parathyroid Pathology. Objectives. The normal parathyroid 11/10/2012

Enterprise Interest Nothing to declare

- Selected Tumors of the Skin Appendages - Primary vs. Metastasis

Whitney A. High, MD, JD, MEng

4/12/2018. MUSC Pathology Symposium Kiawah Island April 18, Jesse K. McKenney, MD

Histology: Its Influence on Therapeutic Decision Making

Liver Specialty Evening Conference. Matthew M. Yeh, MD, PhD Professor of Pathology Adjunct Professor of Medicine University of Washington, Seattle

ACCME/Disclosures. M31078/07 Ondřej Hes 4/13/2016

Transcription:

Diagnosing Mesothelioma in Limited Tissue Samples Papanicolaou Society of Cytopathology Companion Meeting March 12 th, 2016 Sanja Dacic, MD, PhD University of Pittsburgh ACCME/Disclosures GENERAL RULES FOR PATHOLOGIST WHEN DIAGNOSING Correlation with radiographic and intraoperative findings Dr. Sanja Dacic declares she has no conflicts of interest to disclose. A history of asbestos exposure should not be taken into consideration Adequate sample Perform appropriate immunohistochemistry 1

MORPHOLOGICAL CRITERIA FOR DIAGNOSIS OF MALIGNANT CELLULARITY/ZONATION MAJOR CRITERIA Zonation Cellularity Growth pattern Papillae Vascularity Stromal invasion MINOR CRITERIA Cytological atypia Mitoses Necrosis WHO 2015 Am J Surg Pathol 2000; 24(9):1183-1200. WHO 2015 ZONATION PLEURITIS STROMAL INVASION BENIGN PLEURA 2

How many pathologists are willing to diagnose mesothelioma in effusion cytology specimens? RESULTS OF MULTI-INSTITUTIONAL SURVEY 65% make a definitive diagnosis of MM in effusion material 94% of these stated that it is true for both primary and recurrence 63% stated that their clinicians would treat based on cytology diagnosis of MM Pintal A. et al. Cancer Cytopath 2013 DIAGNOSIS OF MM IN EFFUSION SAMPLES Mesothelioma Reactive mesothelial cells NO Inability to assess stromal invasion Minimal cytological atypia YES Architectural atypia large groups of mesothelial cells with knobby borders High cellularity Monotonous population of cells without easily identifiable benign mesothelial cells Pintal A. et al. Cancer Cytopath 2013 Courtesy of Dr. Sara Monaco, UPMC 3

SPECTRUM OF CHALLENGING CASES ROLE OF IMMUNOHISTOCHEMISTRY IN EFFUSION CYTOLOGY To support a diagnosis of MM vs. other malignancies To support a diagnosis of MM vs. reactive mesothelial cells Courtesy of Dr. Sara Monaco, UPMC VS. ADENOCARCINOMA IMMUNOHISTOCHEMISTRY OF EPITHELIOID VS. METASTATIC CARCINOMA MESOTHELIAL MARKERS SENSITIVITY/ SPECIFICITY Calretinin >90% CK5/6 75-100% WT1 70-90% (~100%) D2-40 85% ADENOCA MARKERS SENSITIVITY/ SPECIFICITY MOC31 >95% BerEP4 >95% BG8 (Lewis Y) >90% B72.3 25-85% (>95%) TTF1 >80% (High) MARKER SENSITIVITY (%) SPECIFICITY VS. LUNG TTF-1 Napsin A BREAST ER PR GCDFP15 Mammaglobin KIDNEY PAX8 PAX2 RCC ~80 ~80 NA NA 30-40 50-85 70-100 80 Up to 85 High High NA NA High High Unknown Unknown 75-90 WHO 2015 4

SARCOMATOID, DESMOPLASTIC AND BIPHASIC IMMUNOHISTOCHEMISTRY AND SARCOMATOID MARKER CYTOKERATIN (AE1/3,CAM5.2,CK7) CALRETININ DIAGNOSTIC USE Focal, weak, variable Usually focal in <10% of cells Sarcomatoid <10% Biphasic 10-15% D2-40 Usually helpful Other (WT-1, CK5/6, Ber-EP4, CEA, Not helpful MOC31) Desmoplastic <2% IMMUNOHISTOCHEMISTRY MESOTHELIAL HYPERPLASIA VS. Potential IHC markers in separation between benign and malignant mesothelial proliferations ANTIBODY HYPERPLASIA (%) (%) Desmin 85 10 EMA 20 80 p53 0 45 GLUT-1 3 67 IMP3 0 73 BAP-1 0 15-81 Attanoos RL. et al. Histopathology. 2003;43(3):231 8; Monaco S. et al. AJCP 2011; 135 (4):619 27; Shi M. et al. AJSP 2011; 33(6): 878; Bott M. et al. Nat Genet 2011; 43(7) : 668; Testa JR et al. Nat Genet 2011; 43(10):1022; Andrici J et al. Mod Pathol 2015(28):1360 20 5

BENIGN MESOTHELIAL CELLS VS. MM Desmin EMA p53 Diagnostic GLUT-1 Difficulties (glucose GLUT-1 transporter IHC 1) BENIGN MESOTHELIAL CELLS VS. MM Reactive 85% 20% 0% Reactive 3% 10% 80% 45% Malignant Malignant 67% % positive cases Attanoos RL. et al. Histopathology. 2003;43(3):231 8 21 Monaco et al. AJCP 2011; 135 (4):619 27. BAP1 (BRCA1-associated protein 1) IMMUNOHISTOCHEMISTRY IN MM Singhi A. et al. Mod Pathol 2016; 29:14-24 6

IMMUNOHISTOCHEMISTRY MESOTHELIAL HYPERPLASIA VS. In the individual case, immunohistochemical staining reactions are simply too variable to be relied upon, and we do not recommend their use. Churg A, Cagle PT and Roggli VL. Tumors of the serosal membranes, AFIP Atlas of Tumor Pathology Series 4, pg. 100 (2006) While certain immunohistochemical stains are more likely to show positivity in benign proliferations and others in malignant proliferations, they should not be solely relied on for diagnosis in individual cases.. Husain A.et al. Guidelines for pathologic diagnosis of MM, 2013 Arch Pathol Lab Med A relatively large number of immunohistochemical markers for distinguishing between malignant mesothelioma and reactive mesothelial proliferations have been investigated, but the results of these studies remain controversial. No marker or combination of markers has yet been identified that can be used with confidence for routine diagnostic work in the differential diagnosis. WHO 2015 25 Nature Genetics 2016; Feb 29 on line GENETIC ALTERATIONS IN MALIGNANT 9p21 DELETION AND HISTOLOGY Loss of p16 (9p21) is the most common genetic alteration in MM Homozygous deletion, point mutation, methylation % 100 80 60 40 20 0 Epithelioid Biphasic Sarcomatoid 27 28 7

DIAGNOSTIC UTILITY OF p16 DELETION APPROACH TO EFFUSION CYTOLOGY SAMPLES Fluid specimens Paraffin embedded tissue Modified from AJSP 2016, 40 (1) ATYPICAL MESOTHELIAL PROLIFERATION BAP1 IHC p16 BAP1- BAP1+ CEP9 p16 FISH Not deleted Deleted Not deleted Deleted Ilei et al. Cancer Cytopath 2003; 99(1): Chiosea et al. Mod Pathol 2008 Jun;21(6):742-7. Husain et al. Arch Pathol Lab Med ; 2012 Guidelines Deleted 29 DIAGNOSIS OF MM ESTABLISHED MM NOT EXCLUDED 2015 WHO classification of mesothelial tumors HISTOLOGICAL SUBTYPING OF EPITHELIOID Diffuse Malignant Mesothelioma Epithelioid Sarcomatoid Desmoplastic Biphasic Localized Malignant Mesothelioma Trabecular Tubulopapillary Micropapillary Epithelioid Sarcomatoid Biphasic Well-differentiated papillary mesothelioma Solid Pleomorphic 8

HISTOLOGICAL SUBTYPING OF EPITHELIOID ACCURACY OF SUBTYPING BIOPSY VS. RESECTION Kadota et al. JTO 2011 Chirieac et al. (submitted) SUMMARY Diagnosis of malignant mesothelioma in effusion and small biopsy specimens is possible and requires multidisciplinary approach Immunohistochemistry must be performed to confirm mesothelial origin Distinction between benign and malignant mesothelial proliferations remains a significant diagnostic problem Deletion of 9p21 (p16) as determined by FISH and BAP1 IHC may be diagnostically helpful 35 9